These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 3187940)

  • 1. Spuriously low levels of protein C with a Protac activation clotting assay.
    de Moerloose P; Reber G; Bouvier CA
    Thromb Haemost; 1988 Jun; 59(3):543. PubMed ID: 3187940
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of a new venom-based clotting assay of protein C.
    Cooper PC; Cooper SM; Goodfellow KJ; Hickey KP; Kitchen S; Makris M
    Int J Lab Hematol; 2008 Oct; 30(5):437-43. PubMed ID: 19046320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Automated assay method for protein C anticoagulant activity].
    Iijima K; Kameo Y; Hara I; Murakami F; Nakamura K
    Rinsho Byori; 1992 Jun; 40(6):645-8. PubMed ID: 1513037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoassay by particle counting for coagulation testing: application to the determination of protein C.
    Poncelet S; Lavenne E; Limet JN; Collet-Cassart D
    J Clin Chem Clin Biochem; 1990 Mar; 28(3):181-3. PubMed ID: 2329324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Initial experience in the diagnosis of thrombophilia due to activated protein C resistance].
    Barkagan ZS; Gervaziev VB; Tsyvkina LP; Mamaev AN; Karpenko AA; Tseĭmak IIa
    Ter Arkh; 1997; 69(2):35-7. PubMed ID: 9173574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A method for testing APC resistance in thrombophilic patients.
    Sochynsky CL; Joyner A; Ortel TI
    Am Clin Lab; 1994 Jul; 13(7):26-7. PubMed ID: 10147384
    [No Abstract]   [Full Text] [Related]  

  • 7. [Recent progress on analysis of blood coagulation factors and fibrinolytic agents; protein C].
    Onizawa M
    Rinsho Byori; 1989 Apr; Spec No 81():220-3. PubMed ID: 2754809
    [No Abstract]   [Full Text] [Related]  

  • 8. [Blood coagulation-fibrinolysis tests by a biochemical method].
    Fukuda C; Iijima K; Nakamura K
    Rinsho Byori; 1993 Jul; 41(7):743-9. PubMed ID: 8361043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.
    Johnstone IB; Martin CA
    Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plasma coagulation assay for an activated protein C-independent anticoagulant activity of protein S.
    van Wijnen M; van 't Veer C; Meijers JC; Bertina RM; Bouma BN
    Thromb Haemost; 1998 Dec; 80(6):930-5. PubMed ID: 9869163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Studies on low protein C-expression in severe sepsis].
    Manekeller S; Hertfelder HJ; von Spiegel T; Hering R; Putensen C; Schroeder S
    Zentralbl Chir; 2005 Aug; 130(4):362-7. PubMed ID: 16103962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma.
    Duchemin J; Pittet JL; Tartary M; Béguin S; Gaussem P; Alhenc-Gelas M; Aiach M
    Thromb Haemost; 1994 Mar; 71(3):331-8. PubMed ID: 8029798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rapid determination of protein C activity].
    Nicham F; Guichaoua JF; Contant G; Martinoli JL
    Ann Biol Clin (Paris); 1988; 46(10):805-9. PubMed ID: 3232870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter comparison of five functional and two immunological assays for protein C.
    Mannucci PM; Boyer C; Tripodi A; Viganò-D'Angelo S; Wolf M; Valsecchi C; D'Angelo A; Meyer D; Larrieu MJ
    Thromb Haemost; 1987 Feb; 57(1):44-8. PubMed ID: 3590079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic and therapeutic measures in congenital blood coagulation disorders].
    Eggert JH
    Dtsch Zahnarztl Z; 1982 Nov; 37(11):877-84. PubMed ID: 6816566
    [No Abstract]   [Full Text] [Related]  

  • 17. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
    Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
    Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.
    Camire RM; Kalafatis M; Tracy PB
    Biochemistry; 1998 Aug; 37(34):11896-906. PubMed ID: 9718313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical diagnosis of thrombosis and blood coagulation tests].
    Watanabe K
    Rinsho Byori; 1998 Mar; 46(3):235-44. PubMed ID: 9564763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of arginine-8-vasopressin and 1-deamino-8-D-arginine-vasopressin on ACTH secretion in rats.
    László FA; Janáky T; Julesz J; Kárteszi M; Makara GB; Stark E
    Endocrinol Exp; 1983 Jun; 17(2):133-6. PubMed ID: 6309504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.